Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.45 |
| ▸ | USP2 | O75604 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27275304 | 0.95 | TSHR (0.44) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL18975979 | 0.93 | CYP3A4 (0.50) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL17953962 | 0.89 | CYP2D6 (0.55) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL10260816 | 0.89 | TSHR (0.51) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL27275355 | 0.88 | CYP3A4 (0.49) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL16627077 | 0.87 | USP2 (0.38) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL18482094 | 0.86 | CYP3A4 (0.57) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL21216999 | 0.83 | TSHR (0.47) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL17066203 | 0.83 | TSHR (0.43) | CYP2D6CYP3A4CYP1A2USP2TP53 | |
| SCHEMBL27275281 | 0.81 | USP2 (0.36) | CYP2D6CYP3A4CYP1A2USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-06-28 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3133/4885CYP3A4 2929/4885CYP1A2 3702/4885 |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CYP2D6 3133/4885CYP3A4 2929/4885CYP1A2 3702/4885 |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | PADI4, PADI1, PADI2 | CYP2D6 429/4885CYP3A4 85/4885CYP1A2 442/4885 |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | CDK6, CDK4, CDK7 | CYP2D6 814/4885CYP3A4 1184/4885CYP1A2 2108/4885 |
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | PADI4, PADI1, PADI2 | CYP2D6 491/4885CYP3A4 179/4885CYP1A2 248/4885 |
| US-20180179203-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3133/4885CYP3A4 2929/4885CYP1A2 3702/4885 |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP2D6 2931/4885CYP3A4 3536/4885CYP1A2 3059/4885 |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | CYP2D6 3038/4885CYP3A4 1363/4885CYP1A2 2558/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP2D6 2931/4885CYP3A4 3536/4885CYP1A2 3059/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | CYP2D6 460/4885CYP3A4 233/4885CYP1A2 380/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | CYP2D6 2931/4885CYP3A4 3536/4885CYP1A2 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.